SpectraCure AB publishes Quarterly Report 2, 2021

Second Quarter 2021

Figures for 2021 and 2020 refer to the Group.

  • Other operating income amounted to KSEK 1 673 (872)
  • Result after taxes amounted to KSEK -6 955 (-4 810)
  • Basic and diluted earnings per share: SEK -0,07 (-0,05)
  • Cash flow from operating activities amounted to KSEK -11 206 (-5 775).

First half year 2021

Figures for 2021 and 2020 refer to the Group.

  • Other operating income amounted to KSEK 3 270 (2 057)
  • Result after taxes amounted to KSEK -11 728 (-8 594)
  • Basic and diluted earnings per share: SEK : -0,12 (-0,10)
  • Cash flow from operating activities amounted to KSEK -11 809 (-5 342)
  • Solidity: 92 (88)%

Significant events during the second quarter of 2021

  • The election committee decided to propose re-election of the board members Ulf Bladin, Hans Bornefalk, Ingemar Kihlström, Katarina Svanberg and Sune Svanberg. Ingemar Kihlström was proposed as new Chairman of the Board. Masoud Khayyami declined re-election.The election committee decided to propose Homer Pien as new board member.
  • Johan Folkunger started as SpectraCure’s new CEO on May 3, 2021.
  • SpectraCure identified relevant endpoints to be able to conduct an extended phase 2b study. The further study aims to validate SpectraCure’s treatment method and the clinical effect based on the modified endpoints in a sufficiently large patient base.
  • SpectraCure’s new generation of treatment system was approved by the US Food and Drug Administration (FDA) for use in clinical trials for treatment of prostate cancer recurrence. The system will replace the existing system in ongoing clinical study.

Significant events after the end of the period

There are no significant events to report.